| INTRODUCTION

Congenital infection with cytomegalovirus (cCMV) is common in Wes-
tern countries such as the Netherlands, with a birth prevalence of 0.53%. 1, 2 A meta-analysis of the worldwide literature revealed an overall birth prevalence of 0.64%. 3 An infant may acquire cCMV when its mother encounters or reencounters the virus during pregnancy, which is transmitted through bodily fluids. Approximately 10%-15% of infants infected congenitally have clinical evidence of the disease (are symptomatic) at birth. 4 Symptomatic infants present with symptoms such as intrauterine growth retardation, low birth weight, prematurity and hepatosplenomegaly. 5 Contrarily, the majority of infected infants is asymptomatic at birth. In approximately 7%-25%, asymptomatic infants develop symptoms of the infection later in life. 5, 6 The most common postnatal symptom of cCMV infection is sensorineural hearing loss (SNHL), presenting in 15%-65% of infected children. [7] [8] [9] [10] Additional symptoms or comorbidities associated with cCMV are visual impairment, cognitive and motor deficits which can result in neurodevelopmental delay and balance problems. In addition, these children are prone to neurodevelopmental dysfunction such as intellectual disability, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and pervasive developmental disorder (PDD).
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The SNHL is often progressive in the first 4 years of life for both asymptomatic and symptomatic CMV infected children. 14, 15 When it advances to severe to profound SNHL, cochlear implantation may be considered. Considering the comorbidities associated with cCMV, the question arises whether cCMV children are able to achieve the same performance level with a cochlear implant (CI) compared to non-cCMV children with a CI. A growing number of studies have investigated the performance of cCMV children after cochlear implantation on various speech perception, speech production, receptive language and auditory performance outcomes. A systematic review by Shin et al. 9 reviewed the literature up to 2011 mainly focusing on the effect of antiviral medication on cCMV related SNHL and secondarily the effect of cochlear implantation on cCMV-related SNHL. As for the results on cochlear implantation, they found contradictory results in a combination of case-control studies and case series: some studies reported equal performance in cCMV children compared to non-cCMV children, often 1 year after implantation. Other studies found lower levels of CI performance in cCMV children compared to non-cCMV children. The effect of cCMV-related comorbidities on CI performance was not investigated specifically. This can be a major interest to analyse additionally. The primary aim of this systematic review was to evaluate CI performance in children deafened by cCMV compared to non-cCMV children. Our secondary aim was to investigate the effect of cCMV-related comorbidities on CI performance in cCMV children.
| ME TH ODS
| Ethical considerations
No ethical considerations were made as this is a review of existing literature.
| Search and selection
A systematic literature search in PubMed, Embase and the Cochrane library was conducted from database inception up to the 15th of May 2017. Search terms were limited to the terms:
"children," "cochlear implant" and "performance" with all relevant synonyms (see Table S1 ). To avoid a too narrow search, we did not search on terms corresponding to "CMV." Duplicates were removed. Titles and abstracts were independently screened by sets of two investigators each (E.H., F.v.H., J.M.L.H., S.F.v.d.H., J.V.) using predetermined inclusion and exclusion criteria. Studies were included when they examined speech perception, speech production, receptive language and auditory performance in children with SNHL due to cCMV infection after cochlear implantation. Exclusion criteria were adult patients and/or single-sided deafness. Commentaries, systematic reviews, non-English/Dutch studies and non-human studies were excluded. Unpublished studies were not excluded.
Eligible full-text articles were retrieved, and authors were emailed if a full text was unavailable. Full texts of eligible studies were independently screened by sets of two investigators each (E.H.,
. Differences in opinion were settled by discussion and consensus. Cross-referencing through Scopus was performed after full-text screening to identify titles not found with our initial search. The PRISMA and MOOSE statements were used as a guideline for set-up and writing of this systematic review.
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| Study assessment
Eligible articles were independently assessed by two authors for directness of evidence (DoE), data extractability and risk of bias (RoB) using predefined criteria (see Table 1 ). DoE was scored by evaluating the population, intervention and outcome. In addition,
Key points
• Congenital cytomegalovirus (cCMV) infection is a major cause of sensorineural hearing loss in children.
• In addition to sensorineural hearing loss, congenital cytomegalovirus can cause severe neurodevelopmental comorbidities.
• Cochlear implant performance in children deafened by congenital cytomegalovirus is inferior compared to children deafened by other aetiologies Therapy:
•, Cochlear implantation before the age of 18 years; ○, other therapy.
Outcome:
•, Speech perception, speech production, receptive language or auditory performance;
○, other outcome. 
| Data extraction
Study characteristics, such as study population, non-cCMV group, To answer our second research question, scores of asymptomatic cCMV children versus symptomatic cCMV children and asymptomatic cCMV children versus non-cCMV children were extracted and compared by the reviewers. Between-group analyses were performed using the Mann-Whitney U test for non-parametric numeric data and Fisher's exact test for non-parametric ordinal data in SPSS, and a P-value of <.05 was deemed significant.
| RESULTS
| Search strategy and study selection
As shown in Figure 1 , our search identified 5280 unique articles.
After screening titles and abstracts in inclusion and exclusion criteria, 288 articles were left for full-text screening. Cross-reference screening did not yield additional articles. Corresponding authors were contacted when full texts were not available, which resulted in one additional full text. Consequently, 30 articles were eligible for critical appraisal.
| Assessing quality of studies
The critical appraisal of the 30 studies is presented in Table 1 . compared a cCMV-group to a non-cCMV-group. 5, 13, [18] [19] [20] [21] [22] [24] [25] [26] [27] The non-cCMV group included children with various causes of SNHL in five studies 13, [18] [19] [20] 22, 23, [28] [29] [30] [31] 33, [35] [36] [37] 39, 40 , and children with hereditary SNHL due to connexine 26 (Cx26) mutation in six studies. 5, 21, [24] [25] [26] [27] In one study, a comparison could be distracted, yet no statistical analysis. 23 In seven studies, 32, 34, 38, 41, [43] [44] [45] no comparison with a noncCMV-group was made.
Except for one patient in one study 31 Finally, 12 studies 5,13,18-27 were included in this review because all criteria for DoE were met and data were extractable.
| Data extraction
Primarily, we provided a descriptive table of study results from the study population and comparison group. Meta-analyses of repeatedly reported outcomes (SIR, CAP) were attempted but not reported due to insufficient reporting within the original studies. Computing a forest plot was attempted but failed due to the lack of reporting of measures of uncertainty in the cCMV group and/or control group and great variation in follow-up. Contacting corresponding authors for additional data yielded no response, which made it impossible to gain a sensible result. Secondarily, when available, scores of asymptomatic cCMV children versus symptomatic cCMV children and asymptomatic cCMV children versus asymptomatic non-cCMV children were extracted, displayed in tables and compared by the reviewers.
| Study characteristics
The characteristics of the 12 studies selected after critical appraisal are presented in Table 2 . Sample size in these studies varied from 2 cCMV vs 5 non-cCMV 19 to 16 cCMV vs 131 non-cCMV. 18 Children were divided into two groups based on SNHL with or without comorbidities, respectively: symptomatic and asymptomatic cCMV children. The majority of studies included a combination of symptomatic and asymptomatic cCMV children versus a non-cCMV group. Four studies did not report the presence of comorbidities in the non-cCMV group. 18, 21, 22, 25 As can be seen in Table 2 , one study included only asymptomatic cCMV children and a non-cCMV group without comorbidities. 19 The following outcome measurements were described: auditory performance was tested in six studies [21] [22] [23] [24] [25] 27 , speech perception in four studies 5, 13, 18, 20 , speech production in nine studies 5,18-21,24-27 , receptive language in three studies, 23, 24, 26 and language-social developmental quotients in one study. 13 A list of abbreviations and explanation of outcome measures can be found in Table S2 .
| Prognostic value of cCMV on CI performance
and role of cCMV-related comorbidities
| Primary comparison: cCMV vs non-cCMV
As shown in Table 3 , seven of twelve studies 5, 13, 18, 20, 22, 23, 27 , showed worse outcome in cCMV children (symptomatic and/or asymptomatic) compared to non-cCMV groups on various speech and language outcomes. Six studies 5, 13, 18, 20, 22, 27 explored cCMVrelated comorbidities; in Malik et al. 22 a lower auditory performance was attributed to central nervous system damage and associated cognitive impairment in 11 of 14 cCMV children. In Ciorba et al., 5 a slower progression of speech perception and speech production in the cCMV group compared to a Cx26 group was attributed to concomitant cognitive impairment in the cCMV children. In Yamazaki et al., 13 lower language and social development and word discrimination skills in the cCMV group were contributed to the high(er) rate of comorbidities in this group. A subanalysis on 2 cCMV children with PDD revealed significantly worse word discrimination than the non-cCMV group. In addition, two of four mentally retarded cCMV children revealed significantly worse word discrimination than in the non-cCMV group. In the study by Ramirez and Nikolopoulos, 18 worse speech perception in the cCMV group compared to the non-cCMV group was attributed to ASD in 3 of 16 cCMV children and additional behavioural or language development difficulties in the majority of the cCMV children. In Ferreira et al., 27 a developmental auditory delay in the cCMV group compared to the non-cCMV group was attributed to cognitive deficits in 7 of 11 cCMV children. In Yoshida et al., 20 worse speech production in a cCMV group compared to a noncCMV group was ascribed to prematurity and motor delay in 3 of 4 cCMV children. In the study that did not perform a statistical analysis, 2 cCMV children scored the lowest category (4) on the Categories of Auditory Performance Index compared to scores between 1 and 4 in the non-cCMV group. 23 Both cCMV children showed poor compliance and suffered from recurrent otitis media but not from cCMV-related comorbidities. These non-cCMV children all have the genetic mutation Cx26. In sum, the majority of studies found worse outcomes in the cCMV children compared to non-cCMV children, which was attributed by most authors to be related to cCMV comorbidities.
T A B L E 3 Overall results: performance after cochlear implantation in children with cCMV infection compared to a non-cCMV group
| Secondary comparison 1: Asymptomatic cCMV vs non-cCMV
To test the aforementioned hypothesis, we tried to exclude the effect of comorbidities from the comparison by extracting data of children with solely asymptomatic cCMV versus a non-cCMV group which was possible in four studies (Table 4) . None of the non-cCMV children had reported disabilities themselves apart from SNHL. From
Ciorba et al., we extracted the results of 4 asymptomatic cCMV children and 7 Cx26 children which revealed no significant differences in speech perception and production skills. 5 Iwasaki et al. 19 found no differences between 2 asymptomatic cCMV children and 5 noncCMV children. From Yamazaki et al., 13 we extracted the data of 2 asymptomatic cCMV children (without psycho-neurological symptoms) versus 14 non-cCMV children which revealed equal speech perception. In Philips (2010) et al., 21 speech perception and speech production was equal in 5 asymptomatic cCMV children compared to 8 Cx26 children. In sum, none of the four studies comparing asymptomatic cCMV children with non-cCMV children found worse outcomes in the cCMV children. (Table 5) . From Ciorba et al., 5 significantly lower speech perception in the symptomatic cCMV children compared to the asymptomatic children was seen after 6 months. In Yamazaki et al., 13 the symptomatic cCMV children with ADHD, MR, and PDD showed significantly worse language and social skills than the asymptomatic cCMV children. In Philips (2010) et al., 21 higher speech intelligibility ratings were noted in the asymptomatic group, yet not significant most likely due to the limited sample size (3 vs 5). In sum, in two of three studies comparing asymptomatic cCMV children with symptomatic cCMV children found significantly worse outcomes in the symptomatic group.
| Prognostic value of cCMV on CI performance and role of time post-implant
Follow-up ranged from 3 to 77 months. The six studies 5, 13, 18, 20, 22, 27 that showed a significant difference between the cCMV and noncCMV group reported this difference at a single test 13, 18, 20, 27 and most of them at a short follow-up (less than 2 years 5, 13, 20, 22 ). Two studies 18, 20 reported a significantly worse performance in the cCMV children at multiple test moments: in Yoshida et al., 20 a significant difference between a cCMV group and a non-cCMV group before 12-month follow-up was noted, while after more than 12 months, no significant differences were noted. In the analysis of the study by Ramirez and Nikolopoulos 18 , follow-up varied between 1 and 5 year in the cCMV group (4 cases at 1 year, 7 cases at 3 years, 2 cases at 4 years and 3 cases at 5 years). A worse performance than the noncCMV group at the final follow-up year was seen in 38% of cases (P = .04).
Studies reporting no significant differences between cCMV children and non-cCMV groups all had a follow-up of more than 2 years. 19, 21, [24] [25] [26] 4 | DISCUSSION
| Summary of main findings
The aim of this systematic review was to evaluate the prognostic value of cCMV infection as a cause of SNHL on CI performance in cCMV children. In addition, we evaluated the effect of cCMV-related comorbidities on CI performance in cCMV children. Six of seven T A B L E 4 Speech and language outcome after cochlear implantation in children with asymptomatic cCMV infection compared to a noncCMV group Derived from figure. NR, not reported; NS, not significant; SPr, speech production; SP, speech perception; AP, auditory performance; cCMV, congenital cytomegalovirus.
studies that reported worse outcomes after cochlear implantation in cCMV children attributed the inferior results to such comorbidities. 5, 13, 18, 20, 22, 27 Of the five studies who found equal results in cCMV children compared to a non-cCMV group, one study solely included asymptomatic cCMV children and two studies showed inferior results in the cCMV group, yet insignificant due to the small sample sizes. 21, 25 A fourth study with symptomatic children in both the cCMV and the non-cCMV group saw worse CI performance in children with developmental delays from both groups.
The hypothesis that cCMV-related comorbidities can contribute to lower CI performance in cCMV affected children compared to non-cCMV was evaluated in our secondary analyses. The comparison between asymptomatic cCMV children and non-cCMV children without additional disabilities did not reveal unfavourable results in the cCMV group. This finding eliminates an exclusive unfavourable effect of the virus infection itself on CI performance.
Furthermore, the comparison between symptomatic and asymptomatic cCMV children did show favourable results in the asymptomatic cCMV group on some outcome measures. This finding suggests that the comorbidities associated with cCMV are predictive of lower speech and language outcomes rather than the virus infection itself. 5, 13, 19 Albeit, it is worth mentioning that data were gathered only from studies where individual results could be deducted, meaning data were not used when authors did not present them individually.
An evident pattern between the severity of comorbidities and the outcome in cCMV children after cochlear implantation could not be extracted from the studies in this review. An attempt was made, yet several characteristics of the studies included in this review made this analysis impossible. The studies that did not find a significant difference between cCMV and non-cCMV children, reported a variety of comorbidities in the cCMV group such as motor impairment, behavioural difficulties, as well as cognitive impairment. The non-cCMV groups in these studies had either no disabilities 5, 13, 19, 20, 27 , no reported disabilities 18, 22, 25 or the same amount of comorbidities 23, 24, 26 as the cCMV children. As a result we
were not able to recognise a pattern between the severity of comorbidities and speech and language development.
The majority of the studies that found lower performance in the cCMV group did so within 2 years after implantation. Lower performance mostly disappeared after a longer follow-up. This indicates that CI performance in cCMV children may be delayed but can progress to the level of other children after 2 years. This finding emphasises the benefit of counselling patients and their parents during the first years of speech and language development and explaining that cCMV children may take longer to achieve similar results as non-cCMV children but that they are able to achieve a similar level of speech and language development in approximately 2 years.
| Comparison with literature
The finding of a lower CI performance score in cCMV implantees compared to other aetiologies is in agreement with the systematic review performed in 2011. 9 In their subanalysis on outcome of surgical therapy for CMV-related SNHL, the authors state that children with congenital CMV will advance more slowly than those with other causes of SNHL. However, no analysis was performed to explore the role of associated comorbidities. The current study adds knowledge to the latter question.
T A B L E 5 Speech and language outcome after cochlear implantation in children with symptomatic cCMV infection compared to asymptomatic cCMV infection Methodologically, the current review differs from the previous. 9 The emphasis on the effect of cCMV and related comorbidities on speech and language development after cochlear implantation resulted in a broad search up to 2017 without the use of automated implosions through the databases described earlier. Our search strategy resulted in twelve comparative studies that were deemed valid for data extraction, of which only four were included in the earlier review. All seven articles in that review were included in the original search results of this review, indicating no articles were missed with this extensive search. All but one of the articles included in the previous review were included for critical appraisal in ours except for one case report. 46 Certainly, this systematic review also has its limitations. A limitation of this review is that a meta-analysis could not be performed, due to previously mentioned reasons.
| CONCLUSION
This systematic review shows that children deafened by cCMV are associated with impaired CI performance compared to non-cCMV implantees. In the majority of studies, the cCMV group reached lower levels of CI performance, especially in the first years post-implant.
Inferior CI performance in cCMV children was attributed to comorbidities in the majority of studies and confirmed by additional statistical comparisons by the reviewers. Therefore, we urge clinicians to take into account the negative effects of comorbidities associated with cCMV-related deafness during the counselling of cCMV implantees.
Regardless of the above mentioned, all studies revealed that children with CMV related SNHL benefit from cochlear implantation.
ACKNOWLEDGEMENT
We would like to thank Hanneke Bruijnzeel, MD for her efforts in the earlier stages of setting up this research.
CONF LICT OF I NTEREST
None.
O R C I D
V.J.C. Kraaijenga http://orcid.org/0000-0001-8211-9731
